MicroStrategy Acquires 6,556 Bitcoin For $555.8 Million
MicroStrategy (NASDAQ: MSTR) has once again purchased more bitcoin following the sale of its shares on the open market via
Read more
Author: Jay Lutz
Mako Mining Records Gold Sales Of 10,817 Ounces In Q1
Mako Mining (TSXV: MKO) this morning released preliminary first quarter results, highlighted by the production of 12,228 ounces of gold
Read more
Kinross Gold: Fire Shuts Down Their Largest Operation
If you want an indicator for just how positive gold sentiment is right now, Kinross Gold (TSX: K) is perhaps
Read more
Gold, Risk, & Geopolitics: Fortuna Mining Exits Burkina Faso
Fortuna Mining (TSX: FVI) evidently wants out of the Burkina Faso business. On Friday, the company announced that they have
Read more
Mako Mining Q4 Earnings: Holding Steady
Fourth quarter earnings are now steadily rolling in from the small scale producers out there, and well, in this environment,
Read more
Newmont Completes $4 Billion Asset Divesture Program
While junior explorers and developers have rushed over the last twelve months to secure a spot at the table for
Read more
Tilray Brands Proposes Reverse Split Of Up To 20-To-1 To Regain Nasdaq Compliance
Tilray Brands (TSX: TLRY) is seeking shareholder approval to conduct a reverse stock split in an effort to regain compliance
Read more
Hercules Metals Set To Imminently Launch 12,000 Metre Drill Program
Hercules Metals (TSXV: BIG) is set to “imminently” launch a 12,000 metre drill campaign at its flagship Hercules project in
Read more
Power Metallic Hits 6.37% Copper Equivalent Over 1.0 Metre, Expanding Tiger Zone
Power Metallic (TSXV: PNPN) has continued to see success with the drill bit, with the latest assay results expanding the Tiger zone following the intersection of Lion-style polymetallic mineralization.
Read more
Cardiol Sees First Patient Enrolled Under Phase III MAVERIC Clinical Trial
Cardiol Therapeutics (TSX: CRDL) has reached a major milestone with the announcement that the first patients have been enrolled into a phase III clinical trial for its lead drug candidate, CardiolRx™.
Read more